These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1971348)

  • 1. Suppression of HIV antigenaemia by AL721.
    Shinitzky M; Skornick Y
    Lancet; 1990 May; 335(8700):1281-2. PubMed ID: 1971348
    [No Abstract]   [Full Text] [Related]  

  • 2. Ineffectiveness of AL721 in HIV disease.
    Peters BS; Bennett JM; Jeffries DJ; Knox K; Kocsis A; Pinching AJ
    Lancet; 1990 Mar; 335(8688):545-6. PubMed ID: 1968558
    [No Abstract]   [Full Text] [Related]  

  • 3. NIH-sponsored clinical trials begin for antiviral drug AL721.
    Bennett J
    Am J Nurs; 1988 Apr; 88(4):432. PubMed ID: 3279780
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of AIDS with AL-721.
    Klajman A
    Isr J Med Sci; 1990 Jan; 26(1):2-4. PubMed ID: 2179156
    [No Abstract]   [Full Text] [Related]  

  • 5. [Epidemiological news on infectious diseases].
    Vella S; Rocchi G
    Medicina (Firenze); 1988; 8(2):233-4. PubMed ID: 2852294
    [No Abstract]   [Full Text] [Related]  

  • 6. Controversial AIDS drug for US market.
    Barinaga M
    Nature; 1988 Apr; 332(6164):475. PubMed ID: 3357506
    [No Abstract]   [Full Text] [Related]  

  • 7. Reduction of circulating HIV antigens in seropositive patients after treatment with AL-721.
    Yust I; Vardinon N; Skornick Y; Zakuth V; Hasner A; Shinitzky M
    Isr J Med Sci; 1990 Jan; 26(1):20-6. PubMed ID: 2179157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atopic dermatitis provoked by AL721 in a patient with acquired immunodeficiency syndrome.
    Wolf R; Ophir J; Yust I
    Ann Allergy; 1991 May; 66(5):421-3. PubMed ID: 2035906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AL721, a novel membrane fluidizer.
    Antonian L; Shinitzky M; Samuel D; Lippa AS
    Neurosci Biobehav Rev; 1987; 11(4):399-413. PubMed ID: 3325866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open study of AL-721 treatment of HIV-infected subjects with generalized lymphadenopathy syndrome: an eight week open trial and follow-up.
    Grieco MH; Lange M; Buimovici-Klein E; Reddy MM; Englard A; McKinley GF; Ong K; Metroka C
    Antiviral Res; 1988 Apr; 9(3):177-90. PubMed ID: 2456739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, dose-ranging trial of AL 721 in patients with persistent generalized lymphadenopathy and AIDS-related complex.
    Mildvan D; Buzas J; Armstrong D; Antoniskis D; Sacks HS; Rhame FS; Mosbach EW; Pettinelli C
    J Acquir Immune Defic Syndr (1988); 1991; 4(10):945-51. PubMed ID: 1890604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
    Chaisson RE; Leuther MD; Allain JP; Nusinoff-Lehrman S; Boone GS; Feigal D; Volberding P
    Arch Intern Med; 1988 Oct; 148(10):2151-3. PubMed ID: 3263098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid rebound of serum human immunodeficiency virus antigen after discontinuing zidovudine therapy.
    Spear JB; Benson CA; Pottage JC; Paul DA; Landay AL; Kessler HA
    J Infect Dis; 1988 Nov; 158(5):1132-3. PubMed ID: 3183424
    [No Abstract]   [Full Text] [Related]  

  • 14. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1989 Dec; 262(23):3254. PubMed ID: 2585664
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction of p24 antigen levels in asymptomatic patients using twice-daily zidovudine.
    Gill S; Thin N; Cordery M; Spacey B; Barlow D
    AIDS; 1989 Jan; 3(1):48-9. PubMed ID: 2496716
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of a novel compound (AL 721) on HTLV-III infectivity in vitro.
    Sarin PS; Gallo RC; Scheer DI; Crews F; Lippa AS
    N Engl J Med; 1985 Nov; 313(20):1289-90. PubMed ID: 2414659
    [No Abstract]   [Full Text] [Related]  

  • 17. [Development of HIV 1 antigenemia during treatment with azidothymidine (AZT): follow-up of 90 patients for a year].
    Berlie HC; Berlioux J; Daguet GL
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):685-9. PubMed ID: 2571970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is AL721 really a lipid fluidity modulating agent?
    Offner FA; Traill KN; Winter U; Wick G
    J Invest Dermatol; 1988 Dec; 91(6):607-8. PubMed ID: 3192959
    [No Abstract]   [Full Text] [Related]  

  • 19. New developments in antiretroviral drug therapy for HIV infection.
    Johnson VA
    AIDS Clin Rev; 1992; ():69-104. PubMed ID: 1318738
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prospects in the treatment of AIDS. II. AZT and related compounds; practical conclusions].
    Grieb P
    Pol Arch Med Wewn; 1992; 87(4-5):316-23. PubMed ID: 1381825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.